ARTICLE | Emerging Company Profile
Triplet debuts with $59M, therapies for repeat expansion disorders
Triplet aims to treat repeat expansion disorders by targeting the DNA damage response pathway
December 17, 2019 11:30 AM UTC
Updated on Dec 17, 2019 at 11:14 PM UTC
When new research emerged last year pegging the DNA damage response pathway as a main driver of repeat expansion disorders, rather than the genetic mutations themselves, Atlas Venture co-founded and seeded Triplet with $10 million to design therapies based on the research. The company debuted Tuesday with a $49 million series A led by MPM Capital and Pfizer Ventures.
Atlas, Invus, Partners Innovation Fund and Alexandria Venture Investments also participated in the round, which Triplet Therapeutics Inc. expects to last about two years and allow it to enter the clinic, President and CEO Nessan Bermingham told BioCentury. ...